

Alexander F Lipka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/997036/publications.pdf>

Version: 2024-02-01

11
papers

147
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

211
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2015, 282, 123-125.	2.3	26
2	Ephedrine treatment for autoimmune myasthenia gravis. <i>Neuromuscular Disorders</i> , 2017, 27, 259-265.	0.6	26
3	Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. <i>Neurology</i> , 2020, 94, e511-e520.	1.1	24
4	SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 70-77.	3.8	20
5	Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe. <i>Muscle and Nerve</i> , 2017, 55, 819-827.	2.2	12
6	Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials. <i>BMJ Open</i> , 2015, 5, e007863.	1.9	11
7	Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome. <i>Neuromuscular Disorders</i> , 2021, 31, 622-632.	0.6	10
8	Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 88.	2.7	8
9	Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome. <i>Muscle and Nerve</i> , 2020, 62, 111-114.	2.2	6
10	The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 24-29.	4.0	3
11	Activity limitations in myasthenia gravis and relation to clinical variables. <i>Muscle and Nerve</i> , 2017, 56, 64-70.	2.2	1